Page 135 - Read Online

Table 5: Comparison of virologic response rates between males and females in the whole sample
Whole sample (n = 100) Chi-square test P value

Male (n = 55) Female (n = 45)
RVR 5/55 (9.1%) 6/45 (13.3%) 0.455 0.5
cEVR 13/55 (23.6%) 16/45 (35.6%) 1.708 0.191
pEVR 16/55 (29.1%) 13/45 (28.9%) 0 0.982
Absence of RVR or cEVR or pEVR 21/55 (38.2%) 10/45 (22.2%) 2.947 0.086

ETVR 30/55 (54.5%) 30/45 (66.7%) 1.515 0.218
Relapse rate 11/30 (36.7%) 9/30 (30%) 0.30 0.584
SVR 19/55 (34.5%) 21/45 (46.7%) 1.515 0.218
Data are shown as n/N (%). RVR: rapid virological response; EVR: early virological response; cEVR: complete EVR; pEVR: partial EVR; ETVR: end-of-treatment
virologic response; SVR: sustained virological response
Table 6: Comparison of virologic response rates between males and females respectively in the < 50 and > 50 year-aged
patient samples
< 50 year sample (n = 55) > 50 year sample (n = 45)
Chi-square Chi-square
Male (n = 34) Female (n = 21) test P value Male (n = 21) Female (n = 24) test P value
RVR 4/34 (11.8%) 5/21 (23.8%) 1.376 0.241 1/21 (4.8% ) 1/24 (4.2% ) 0.009 0.923
CEVR 11/34 (32.4%) 12/21 (57.1%) 3.279 0.070 2/21 (9.5% ) 4/24 (16.7% ) 0.494 0.48
PEVR 4/34 (11.8%) 2/21 (9.5%) 0.067 0.796 12/21 (57.1% ) 11/24 (45.8% ) 0.573 0.44
Absence of RVR or
cEVR or pEVR 15/34 (44.1%) 2/21 (9.5%) 7.275 0.007 6/21 (28.6% ) 8/24 (33.3% ) 0.118 0.73
ETVR 19/34 (55.9%) 19/21 (90.5%) 7.275 0.007 11/21 (52.4% ) 11/24 (45.8% ) 0.192 0.66
Relapse rate 6/19 (31.6%) 5/19 (26.3%) 0.128 0.7206 5/11 (45.5% ) 4/11 (36.4% ) 0.188 0.66
SVR 13/34 (38.2%) 14/21 (66.7%) 4.199 0.04 6/21 (28.6% ) 7/24 (29.2% ) 0 0.964
Data are shown as n/N (%). RVR: rapid virological response; EVR: early virological response; cEVR: complete EVR; pEVR: partial EVR; ETVR: end-of-treatment
virologic response; SVR: sustained virological response
Table 7: Comparison of virologic response rates between < 50 year-aged and > 50 year-aged male sample and between < 50
year-aged and > 50 year-aged female sample
Male sample (n = 55) Female sample (n = 45)
< 50 years > 50 years Chi-square P value < 50 years > 50 years Chi-square P value
(n = 34) (n = 21) test (n = 21) (n = 24) test

RVR 4/34 (11.8%) 1/21 (4.8%) 0.77 0.38 5/21 (23.8%) 1/24 (4.2%) 3.73 0.0531
cEVR 11/34 (32.4%) 2/21 (9.5%) 3.74 0.053 12/21 (57.1%) 4/24 (16.7%) 8 0.004
pEVR 4/34 (11.8%) 12/21 (57.1%) 12.95 0.0003 2/21 (9.5%) 11/24 (45.8%) 7.187 0.007
Absence of RVR or
cEVR or pEVR 15/34 (44.1%) 6/21 (28.6%) 1.329 0.24 2/21 (9.5%) 8/24 (33.3%) 3.67 0.0553
ETVR 19/34 (55.9%) 11/21 (52.4%) 0.064 0.8 19/21 (90.5%) 11/24 (45.8%) 10.04 0.001
Relapse rate 6/19 (31.6%) 5/11 (45.5%) 0.577 0.44 5/19 (26.3%) 4/11 (36.4%) 0.33 0.56
SVR 13/34 (38.2%) 6/21 (28.6%) 0.536 0.464 14/21 (66.7%) 7/24 (29.2%) 6.32 0.01
Data are shown as n/N (%). RVR: rapid virological response; EVR: early virological response; cEVR: complete EVR; pEVR: partial EVR; ETVR: end-of-treatment
virologic response; SVR: sustained virological response

and 2]. On the other hand, frequency of subjects not of pEVR in males > 50 years compared to < 50
achieving RVR or EVR was significantly higher in men years males. Furthermore, women < 50 years were
> 50 years than in females [Table 7]. No significant characterised by significantly higher rates of cEVR,
differences existed in virological responses in ETVR, SVR and by significantly lower rates of pEVR
subjects > 50 years. compared to women > 50 years [Figure 3].

Influence of age among patients of the same gender Univariate analysis
Analysis performed in subjects of the same gender In univariate analysis, factors associated with SVR
stratified by age showed significantly higher rates were presence of RVR, a lower level of GGT, a degree

126 Hepatoma Research | Volume 2 | May 6, 2016